After professing a hearty appetite for tuck-in M&A last year and signing a string of smaller deals, Stryker is now opening ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies ...

Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

Because of the risks biopsies can pose to patients, the FDA recommends only requiring them as part of trial participation if ...

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...

CytomX Therapeutics is shrinking its headcount by 40% as the biotech regroups and looks at fresh ways to conserve cash.

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...